HyponatremiaSALTEDNCT02103491
Effects of Oral Salt Supplementation on Physical Performance During a Half-ironman
A study testing Salt administration in people with Hyponatremia, run by Camilo Jose Cela University at 1 site in Spain.
Trial summary
Background: Ultradistance athletes frequently consume salt supplements during competitions to compensate the loss of electrolytes by sweating. The aim of this study was to investigate the effectiveness of oral salt supplementation to improve exercise performance during a half-ironman triathlon. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Hyponatremia
- What is being tested?
- Salt administration
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteSpain
- Study dates
- Jun 2013to Aug 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- -Triathletes with previous experience in half-ironman
Who cannot join
- -Potential participants (triathletes) with a previous history of muscle disorder, cardiac or kidney disease or those taking medicines or supplements during the two prior weeks were discarded.
Trial locations and contacts
1 site in 1 country.
Spain1 site
Exercise Physiology Laboratory, Camilo Jose Cela University
Villanueva de la Cañada, Madrid, 28692
About this study
Background: Ultradistance athletes frequently consume salt supplements during competitions to compensate the loss of electrolytes by sweating. The aim of this study was to investigate the effectiveness of oral salt supplementation to improve exercise performance during a half-ironman triathlon. Methodology: Twenty-six experienced triathletes were matched for age, anthropometric data and training status and randomly placed into the salt group (113 mmol Na+ and 112 mmol Cl-) or the control group (cellulose). The experimental treatments were provided in unidentifiable capsules and were ingested before and during the race. Participants competed in a real half-ironman triathlon and race time was measured by means of chip timing. Pre and post-race, body mass, maximal force during a whole-body isometric strength test, maximal height during a countermovement jump, and blood samples were obtained. Sweat samples were obtained during the running section.
Read the detailed description
Participants Forty healthy and well-trained triathletes were recruited by email or through internet announcements to participate in this study. Before enrolling in the investigation, a questionnaire about their medical history, previous training, previous triathlon experience and best race time in half-ironman triathlon races was filled out by each participant. Potential participants with a previous history of muscle disorder, cardiac or kidney disease or those taking medicines during the two prior weeks were discarded. Finally, twenty-six participants were selected and matched (in pairs) for age, anthropometric data, training and best race time. Then, an equal number of triathletes (n = 13) was randomly assigned to the control group or to the salt ingestion group. Main morphological variables, training status and best performance time in the half-ironman distance were similar between these groups (P > 0.05; Table 1). All the participants were informed of the risks and discomforts associated with the experiments and signed a written consent before their participation in this investigation. The study was approved by the Camilo Jose Cela Ethics Committee in accordance with the latest version of the Declaration of Helsinki.
Experimental Protocol Participants were instructed to perform light exercise and to avoid pain-relieving strategies (e.g., analgesic medications, manual massage, ice, etc) the two days before the race. In addition, participants were instructed to avoid any sources of caffeine and alcohol 24 h before the onset of the race. Three hours before the race, participants arrived at an area close to the start line having drunk 500 mL of tap water two hours before arrival. Participants had their habitual pre-competition meal and it was not standardized among participants to avoid affecting participants' pre-competition routines. However, the pre-competition meals were analyzed afterwards and their content in carbohydrates, proteins and salt was similar between groups.
On arrival, participants rested for 10 minutes in a recumbent chair and a 5-mL venous blood sample was drawn from an antecubital vein. The blood was allowed to clot and centrifuged at 5000g to obtain serum. Participants then completed a 10-min standardized warm-up consisting of running, dynamic leg exercises and practice jumps. After that, participants performed two countermovement vertical jumps (CMJ) for maximal height on a force platform (Quattrojump, Kistler, Switzerland) to assess pre-race leg power output. On command, the participant flexed their knees and jumped as high as possible while maintaining the hands on the waist and landed with both feet. The highest values for jump height and the peak muscle leg power during the concentric phase of the jump were used for statistical analysis. Participants were previously familiarized with the jump test.
After that, whole-body isometric muscle strength was measured by means of a hand-held pull gauge (Isocontrol Isométrico, EV-Pro, Spain) set at a frequency of 1000 Hz. For this measurement, participants stand on a 50 × 50 cm iron base connected to a handle-bar by a non-elastic cable. The isometric gauge was inserted within the cable and the height of the cable was individually set to provide a 135º knee flexion while the back and the arms were completely extended. Participants were instructed to perform a maximal pull by for 3-s using their whole body (mainly legs and arms) while maintaining this position. Verbal motivation was provided during the test. An adjustable lumbar-back protector was used for support and protection during the execution. Maximal and mean isometric strength were obtained during the test. Participants were previously familiarized with this measurement.
After that, participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections. This schedule was used to facilitate ingestion and electrolyte absorption during the race. Participants received a sample of these capsules (filled with placebo) the week before the race to practice the ingestion protocol during the transition and the cycling sector. Participants were encouraged to ingest all the capsules in the programmed schedule and to report any incidence during the capsule ingestion throughout the race.
Just 15-min before the race (and after their habitual warm-up), participants were weighed in their competition clothes (without wetsuit) and a segmental bioelectrical impedance analysis was performed (BC-418, Tanita, Japan) to predict pre-to-post race total body water changes. The race started at 12:00 h and consisted of 1.9 km of swimming, 75 km of cycling (1100 m net increase in altitude) and 21.1 km of running. Environment conditions were recorded at 30-min intervals and mean ± SD (range) dry temperature during the event was 22.5 ± 2.7ºC (18.8 - 26.6 ºC) with a relative humidity of 36.8 ± 8.3% (32 - 45%). The swim section was performed in a natural lake with water temperature at 17.5 ± 0.3ºC. All participants wore a neoprene wetsuit during the swim section. Participants drank and consumed food ad libitum and swam, cycled and ran at their own pace with no instructions given by the experimenters (apart from those related to capsule ingestion).
During the second transition (between the cycling and running legs), two sweat patches (Tegaderm+Pad, 3M, US) were placed on the forearm to collect sweat samples. For this purpose, participants went to an area located just outside the transition area and the forearm skin was cleaned with distilled water and alcohol and dried with clean gauze to eliminate any remains of previous sweat from the skin. After this, the sweat patch was firmly adhered to the skin and fastened by an elastic tubular net bandage (Elastofix, Insfarma, Germany). This process took approximately 1-min and this time was subtracted from the final race time of each participant.
Within 1-min of the end of the race, participants went to a finish area and body mass and body bioelectrical impedance were immediately measured using the same apparatus described previously. Participants were instructed to avoid drinking from the finish line till the post-race weighing and an experimenter assured compliance. Then, participants performed two countermovement vertical jumps and the whole-body isometric muscle strength test, as previously described. These performance tests were completed within 5-min of the end of the race. Participants then rested for 5-min and a venous blood sample was obtained. During this resting period, the sweat patches were removed using clean tweezers and placed in a sterile 10 mL- tube. Sweat patches that were detached from the skin or presented a leak were discarded.
After these protocols, the rate of perceived exertion during the race was self-rated using the Borg scale (6 to 20 points) while perceived leg muscle soreness was self-rated using a visual analog scale (0 to 10 points). Participants also filled out a detailed questionnaire about fluid and food intake during the race. Data on this questionnaire were used to calculate fluid, calorie and carbohydrate intake during the race. With this self-reported questionnaire, we also calculated electrolyte intake during the race (apart from the salt ingested with the capsule treatment). Finally, participants reported any incident during the intake of the capsules and the side-effects derived from their ingestion.
Blood and sweat sample analysis The blood was allowed to clot in situ and serum was separated by centrifugation (10 min at 5000 g) and frozen at -80ºC until the day of analysis. At a later date, the serum portion was analyzed for osmolality (1249, Advance 3MO, Spain), sodium, chloride, potassium and magnesium concentrations (Nova 16, NovaBiomedical, Spain). In addition, the serum creatine kinase concentration was measured as a blood marker of muscle damage by means of an autoanalyzer (AU5400, Beckman Coulter, US). The sweat was separated from the patches by centrifugation (10 min at 3000 g), transferred to 5-mL sealed tubes and refrigerated at 4 ºC. At a later date (within 2 days of the race), sweat osmolality was measured with the same osmometer employed for the serum samples while sweat electrolyte concentration were measured using an ion selective electrode analyzer (Cobas 6000, Roche, Madrid, Spain).
Statistical Analysis The normality of each variable was initially tested with the Shapiro-Wilk test. All the variables presented a normal distribution. For the variables obtained once during the experiment (race time, body mass change, sweat electrolyte concentration, self-rated fatigue and muscle soreness, etc) the comparison between groups (salt vs control) was performed using Student's t test for independent samples. For the variables obtained twice during the experiment (body mass, blood variables, jump performance, etc) the comparison between groups was performed by using a mixed model ANOVA (time × treatment) with repeated measures for the variable time. The data were analyzed with the statistical package SPSS version 19.0 (SPSS Inc., Chicago, IL). The significance level was set at P < 0.05. Data are presented as mean ± SD.
- Conditions
- Hyponatremia
- Being tested
- Salt administration, Placebo administration
- Keywords
- Half-ironman, Triathlon, Salt, Exercise, Performance
- Medical subject headings
- Hyponatremia, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Salt administrationDietary supplement
Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.
Placebo administrationDietary supplement
| Study group | Role | What they receive |
|---|---|---|
| Salt administration | Active comparator | Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). Receives: Dietary Supplement: Salt administration |
| Placebo administration | Placebo comparator | In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). Receives: Dietary Supplement: Placebo administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Triathlon race time
Participants will compete in a real half-ironman triathlon and race time will be measured by means of chip timing. The chip timing will be adjusted in the participants's shoe.
Race time will be measured in seconds.
Measured: The experiment will be carried out in 1 day. This variable will be obtained in this unique experimental day.
Changes in blood parameters before and after the race
The serum portion of each blood sample will be analyzed for osmolality (1249, Advance 3MO, Spain), sodium, chloride, potassium and magnesium concentrations (Nova 16, NovaBiomedical, Spain). ). In addition, the serum creatine kinase concentration will be measured as a blood marker of muscle damage by means of an autoanalyzer (AU5400, Beckman Coulter, US).
Blood concentration (in mM) will be determined for each variable.
Measured: The experiment will be carried out in 1 day. This variable will be obtained in this unique experimental day
Sweat samples analysis
The sweat will be obtained with sweat patches (Tegaderm 3m) and it will be separated from the patches by centrifugation (10 min at 3000 g), transferred to 5-mL sealed tubes and refrigerated at 4 ºC. At a later date (within 2 days of the race), sweat osmolality will be measured with the same osmometer employed for the serum samples while sweat electrolyte concentration were measured using an ion selective electrode analyzer (Cobas 6000, Roche, Madrid, Spain).
Sweat electrolyte concentration will be measured in mM.
Measured: The experiment will be carried out in 1 day. This variable will be obtained in this unique experimental day
Secondary outcomes (2)
Changes in total body water content (pre and post-race)
Just 15-min before the race (and after their habitual warm-up), participants will be weighed in their competition clothes (without wetsuit) and a segmental bioelectrical impedance analysis will be performed (BC-418, Tanita, Japan) to predict pre-to-post race total body water changes.
Total body water will be measured in kg.
Measured: The experiment will be carried out in 1 day. This variable will be obtained in this unique experimental day
Changes in whole body isometric force from pre to post-race
Before and just after the race, whole-body isometric muscle strength will be measured by means of a hand-held pull gauge (Isocontrol Isométrico, EV-Pro, Spain) set at a frequency of 1000 Hz. For this measurement, participants will stand on a 50 × 50 cm iron base connected to a handle-bar by a non-elastic cable. The isometric gauge will be inserted within the cable and the height of the cable was individually set to provide a 135º knee flexion while the back and the arms will be completely extended. An adjustable lumbar-back protector was used for support and protection during the execution. Maximal and mean isometric strength were obtained during the test. Participants will be previously familiarized with this measurement.
Measured: The experiment will be carried out in 1 day. This variable will be obtained in this unique experimental day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2014 (estimated)
- Study startJun 2013
- Primary completionJun 2013
- Study completionAug 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HyponatremiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Camilo Jose Cela University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Juan Del Coso, PhD, Principal investigator, Camilo Jose Cela University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02103491
- Sponsor's protocol ID
- UCJC-14
- Acronym
- SALTED
- Status last verified
- Aug 2023
- First submitted
- 26 Mar 2014
- Last updated
- 31 Aug 2023
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Del Coso J, Gonzalez-Millan C, Salinero JJ, Abian-Vicen J, Areces F, Lledo M, Lara B, Gallo-Salazar C, Ruiz-Vicente D. Effects of oral salt supplementation on physical performance during a half-ironman: A randomized controlled trial. Scand J Med Sci Sports. 2016 Feb;26(2):156-64. doi: 10.1111/sms.12427. Epub 2015 Feb 14.
PubMed 25683094
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Oral Salt Supplementation on Physical Performance During a Half-ironman
- ClinicalTrials.gov ID
- NCT02103491
- Acronym / sponsor ID
- SALTED / UCJC-14
- Conditions
- Hyponatremia
- Keywords
- Half-ironman, Triathlon, Salt, Exercise, Performance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Camilo Jose Cela UniversityUniversity, hospital or other
- Study start
- Jun 2013
- Primary completion
- Jun 2013 (actual)
- Study completion
- Aug 2013 (actual)
- First posted
- 4 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Ultradistance athletes frequently consume salt supplements during competitions to compensate the loss of electrolytes by sweating. The aim of this study was to investigate the effectiveness of oral salt supplementation to improve exercise performance during a half-ironman triathlon. Methodology: Twenty-six experienced triathletes were matched for age, anthropometric data and training status and randomly placed into the salt group (113 mmol Na+ and 112 mmol Cl-) or the control group (cellulose). The experimental treatments were provided in unidentifiable capsules and were ingested before and during the race. Participants competed in a real half-ironman triathlon and race time was measured by means of chip timing. Pre and post-race, body mass, maximal force during a whole-body isometric strength test, maximal height during a countermovement jump, and blood samples were obtained. Sweat samples were obtained during the running section.
Detailed description
Participants Forty healthy and well-trained triathletes were recruited by email or through internet announcements to participate in this study. Before enrolling in the investigation, a questionnaire about their medical history, previous training, previous triathlon experience and best race time in half-ironman triathlon races was filled out by each participant. Potential participants with a previous history of muscle disorder, cardiac or kidney disease or those taking medicines during the two prior weeks were discarded. Finally, twenty-six participants were selected and matched (in pairs) for age, anthropometric data, training and best race time. Then, an equal number of triathletes (n = 13) was randomly assigned to the control group or to the salt ingestion group. Main morphological variables, training status and best performance time in the half-ironman distance were similar between these groups (P > 0.05; Table 1). All the participants were informed of the risks and discomforts associated with the experiments and signed a written consent before their participation in this investigation. The study was approved by the Camilo Jose Cela Ethics Committee in accordance with the latest version of the Declaration of Helsinki.
Experimental Protocol Participants were instructed to perform light exercise and to avoid pain-relieving strategies (e.g., analgesic medications, manual massage, ice, etc) the two days before the race. In addition, participants were instructed to avoid any sources of caffeine and alcohol 24 h before the onset of the race. Three hours before the race, participants arrived at an area close to the start line having drunk 500 mL of tap water two hours before arrival. Participants had their habitual pre-competition meal and it was not standardized among participants to avoid affecting participants' pre-competition routines. However, the pre-competition meals were analyzed afterwards and their content in carbohydrates, proteins and salt was similar between groups.
On arrival, participants rested for 10 minutes in a recumbent chair and a 5-mL venous blood sample was drawn from an antecubital vein. The blood was allowed to clot and centrifuged at 5000g to obtain serum. Participants then completed a 10-min standardized warm-up consisting of running, dynamic leg exercises and practice jumps. After that, participants performed two countermovement vertical jumps (CMJ) for maximal height on a force platform (Quattrojump, Kistler, Switzerland) to assess pre-race leg power output. On command, the participant flexed their knees and jumped as high as possible while maintaining the hands on the waist and landed with both feet. The highest values for jump height and the peak muscle leg power during the concentric phase of the jump were used for statistical analysis. Participants were previously familiarized with the jump test.
After that, whole-body isometric muscle strength was measured by means of a hand-held pull gauge (Isocontrol Isométrico, EV-Pro, Spain) set at a frequency of 1000 Hz. For this measurement, participants stand on a 50 × 50 cm iron base connected to a handle-bar by a non-elastic cable. The isometric gauge was inserted within the cable and the height of the cable was individually set to provide a 135º knee flexion while the back and the arms were completely extended. Participants were instructed to perform a maximal pull by for 3-s using their whole body (mainly legs and arms) while maintaining this position. Verbal motivation was provided during the test. An adjustable lumbar-back protector was used for support and protection during the execution. Maximal and mean isometric strength were obtained during the test. Participants were previously familiarized with this measurement.
After that, participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections. This schedule was used to facilitate ingestion and electrolyte absorption during the race. Participants received a sample of these capsules (filled with placebo) the week before the race to practice the ingestion protocol during the transition and the cycling sector. Participants were encouraged to ingest all the capsules in the programmed schedule and to report any incidence during the capsule ingestion throughout the race.
Just 15-min before the race (and after their habitual warm-up), participants were weighed in their competition clothes (without wetsuit) and a segmental bioelectrical impedance analysis was performed (BC-418, Tanita, Japan) to predict pre-to-post race total body water changes. The race started at 12:00 h and consisted of 1.9 km of swimming, 75 km of cycling (1100 m net increase in altitude) and 21.1 km of running. Environment conditions were recorded at 30-min intervals and mean ± SD (range) dry temperature during the event was 22.5 ± 2.7ºC (18.8 - 26.6 ºC) with a relative humidity of 36.8 ± 8.3% (32 - 45%). The swim section was performed in a natural lake with water temperature at 17.5 ± 0.3ºC. All participants wore a neoprene wetsuit during the swim section. Participants drank and consumed food ad libitum and swam, cycled and ran at their own pace with no instructions given by the experimenters (apart from those related to capsule ingestion).
During the second transition (between the cycling and running legs), two sweat patches (Tegaderm+Pad, 3M, US) were placed on the forearm to collect sweat samples. For this purpose, participants went to an area located just outside the transition area and the forearm skin was cleaned with distilled water and alcohol and dried with clean gauze to eliminate any remains of previous sweat from the skin. After this, the sweat patch was firmly adhered to the skin and fastened by an elastic tubular net bandage (Elastofix, Insfarma, Germany). This process took approximately 1-min and this time was subtracted from the final race time of each participant.
Within 1-min of the end of the race, participants went to a finish area and body mass and body bioelectrical impedance were immediately measured using the same apparatus described previously. Participants were instructed to avoid drinking from the finish line till the post-race weighing and an experimenter assured compliance. Then, participants performed two countermovement vertical jumps and the whole-body isometric muscle strength test, as previously described. These performance tests were completed within 5-min of the end of the race. Participants then rested for 5-min and a venous blood sample was obtained. During this resting period, the sweat patches were removed using clean tweezers and placed in a sterile 10 mL- tube. Sweat patches that were detached from the skin or presented a leak were discarded.
After these protocols, the rate of perceived exertion during the race was self-rated using the Borg scale (6 to 20 points) while perceived leg muscle soreness was self-rated using a visual analog scale (0 to 10 points). Participants also filled out a detailed questionnaire about fluid and food intake during the race. Data on this questionnaire were used to calculate fluid, calorie and carbohydrate intake during the race. With this self-reported questionnaire, we also calculated electrolyte intake during the race (apart from the salt ingested with the capsule treatment). Finally, participants reported any incident during the intake of the capsules and the side-effects derived from their ingestion.
Blood and sweat sample analysis The blood was allowed to clot in situ and serum was separated by centrifugation (10 min at 5000 g) and frozen at -80ºC until the day of analysis. At a later date, the serum portion was analyzed for osmolality (1249, Advance 3MO, Spain), sodium, chloride, potassium and magnesium concentrations (Nova 16, NovaBiomedical, Spain). In addition, the serum creatine kinase concentration was measured as a blood marker of muscle damage by means of an autoanalyzer (AU5400, Beckman Coulter, US). The sweat was separated from the patches by centrifugation (10 min at 3000 g), transferred to 5-mL sealed tubes and refrigerated at 4 ºC. At a later date (within 2 days of the race), sweat osmolality was measured with the same osmometer employed for the serum samples while sweat electrolyte concentration were measured using an ion selective electrode analyzer (Cobas 6000, Roche, Madrid, Spain).
Statistical Analysis The normality of each variable was initially tested with the Shapiro-Wilk test. All the variables presented a normal distribution. For the variables obtained once during the experiment (race time, body mass change, sweat electrolyte concentration, self-rated fatigue and muscle soreness, etc) the comparison between groups (salt vs control) was performed using Student's t test for independent samples. For the variables obtained twice during the experiment (body mass, blood variables, jump performance, etc) the comparison between groups was performed by using a mixed model ANOVA (time × treatment) with repeated measures for the variable time. The data were analyzed with the statistical package SPSS version 19.0 (SPSS Inc., Chicago, IL). The significance level was set at P < 0.05. Data are presented as mean ± SD.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Salt administration | Active comparator | Dietary Supplement: Salt administrationParticipants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). |
| Placebo administration | Placebo comparator | Dietary Supplement: Placebo administrationIn the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- -Triathletes with previous experience in half-ironman
Key exclusion criteria (1 listed)
- -Potential participants (triathletes) with a previous history of muscle disorder, cardiac or kidney disease or those taking medicines or supplements during the two prior weeks were discarded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Salt administrationParticipants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections. | Dietary supplement | Salt administration |
| Placebo administration | Dietary supplement | Placebo administration |
Primary outcome
Triathlon race time
Time frame: The experiment will be carried out in 1 day. This variable will be obtained in this unique experimental day.
Participants will compete in a real half-ironman triathlon and race time will be measured by means of chip timing. The chip timing will be adjusted in the participants's shoe. Race time will be measured in seconds.
Changes in blood parameters before and after the race
Time frame: The experiment will be carried out in 1 day. This variable will be obtained in this unique experimental day
The serum portion of each blood sample will be analyzed for osmolality (1249, Advance 3MO, Spain), sodium, chloride, potassium and magnesium concentrations (Nova 16, NovaBiomedical, Spain). ). In addition, the serum creatine kinase concentration will be measured as a blood marker of muscle damage by means of an autoanalyzer (AU5400, Beckman Coulter, US). Blood concentration (in mM) will be determined for each variable.
Sweat samples analysis
Time frame: The experiment will be carried out in 1 day. This variable will be obtained in this unique experimental day
The sweat will be obtained with sweat patches (Tegaderm 3m) and it will be separated from the patches by centrifugation (10 min at 3000 g), transferred to 5-mL sealed tubes and refrigerated at 4 ºC. At a later date (within 2 days of the race), sweat osmolality will be measured with the same osmometer employed for the serum samples while sweat electrolyte concentration were measured using an ion selective electrode analyzer (Cobas 6000, Roche, Madrid, Spain). Sweat electrolyte concentration will be measured in mM.
2 secondary outcomes
Changes in total body water content (pre and post-race)
Time frame: The experiment will be carried out in 1 day. This variable will be obtained in this unique experimental day
Changes in whole body isometric force from pre to post-race
Time frame: The experiment will be carried out in 1 day. This variable will be obtained in this unique experimental day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2023.
- Derived from this study: PubMed 25683094Del Coso J, Gonzalez-Millan C, Salinero JJ, Abian-Vicen J, Areces F, Lledo M, Lara B, Gallo-Salazar C, Ruiz-Vicente D. Effects of oral salt supplementation on physical performance during a half-ironman: A randomized controlled trial. Scand J Med Sci Sports. 2016 Feb;26(2):156-64. doi: 10.1111/sms.12427. Epub 2015 Feb 14.
Related trials for Hyponatremia
RecruitingPhase 3
Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia
Hyponatremia
Enrolling by invitationObservational study
International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia
Hyponatremia Symptomatic, Osmotic Demyelination Syndrome
Active, not recruitingObservational study
Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH
Antidiuretic Hormone, Inappropriate Secretion
Recruiting
Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid Restriction
SIAD - Syndrome of Inappropriate Antidiuresis
Active, not recruitingObservational study
Hyponatremia - Complications, Prognosis, Epidemiology in Finnish Tertiary Care
Hyponatremia, Osmotic Demyelination Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Juan Del Coso, PhD principal investigator
Camilo Jose Cela University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Salt administration in people with Hyponatremia, run by Camilo Jose Cela University at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Triathlon race time (time frame: The experiment will be carried out in 1 day. This variable will be obtained in this unique experimental day.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02103491, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2023.